메뉴 건너뛰기




Volumn 41, Issue 3, 2006, Pages 298-303

Partial treatment interruption of protease inhibitor-based highly active antiretroviral therapy regimens in HIV-infected children

Author keywords

Antiretroviral therapy; Children; HIV; Treatment interruption

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ADEFOVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

EID: 33645096222     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000197078.41150.0d     Document Type: Article
Times cited : (14)

References (23)
  • 1
    • 0035936007 scopus 로고    scopus 로고
    • Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1
    • Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528.
    • (2001) N Engl J Med , vol.345 , pp. 1522-1528
    • Gortmaker, S.L.1    Hughes, M.2    Cervia, J.3
  • 3
    • 0037004510 scopus 로고    scopus 로고
    • The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era
    • Sabin C. The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS. 2002;16(Suppl):S61-S68.
    • (2002) AIDS , vol.16 , Issue.SUPPL.
    • Sabin, C.1
  • 4
    • 4444220301 scopus 로고    scopus 로고
    • Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving HAART
    • Viani RM, Araneta MRG, Deville JG, et al. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving HAART. Clin Infect Dis. 2004;39:725-731.
    • (2004) Clin Infect Dis , vol.39 , pp. 725-731
    • Viani, R.M.1    Araneta, M.R.G.2    Deville, J.G.3
  • 5
    • 9144258622 scopus 로고    scopus 로고
    • Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents
    • Soh CH, Oleske JM, Brady MT, et al. Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents. Lancet. 2003;362:2045-2051.
    • (2003) Lancet , vol.362 , pp. 2045-2051
    • Soh, C.H.1    Oleske, J.M.2    Brady, M.T.3
  • 6
    • 0036701627 scopus 로고    scopus 로고
    • Pediatric HIV in 2002 - A treatable and preventable infection
    • Lyall H. Pediatric HIV in 2002 - a treatable and preventable infection. J Clin Virol. 2002;25:107-119.
    • (2002) J Clin Virol , vol.25 , pp. 107-119
    • Lyall, H.1
  • 7
    • 0347995130 scopus 로고    scopus 로고
    • Treatment of antiretroviral-drug-resistant HIV-1 infection
    • Deeks SG. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet. 2003;362:2002-2011.
    • (2003) Lancet , vol.362 , pp. 2002-2011
    • Deeks, S.G.1
  • 8
    • 0348011587 scopus 로고    scopus 로고
    • Human immunodeficiency virus protease inhibitors
    • Kline MW. Human immunodeficiency virus protease inhibitors. J Pediatr Infect Dis. 2003;22:1085-1087.
    • (2003) J Pediatr Infect Dis , vol.22 , pp. 1085-1087
    • Kline, M.W.1
  • 9
    • 4444315072 scopus 로고    scopus 로고
    • Metabolic complications of HIV therapy in children
    • McComsey GA, Leonard E. Metabolic complications of HIV therapy in children. AIDS. 2004;18:1753-1768.
    • (2004) AIDS , vol.18 , pp. 1753-1768
    • McComsey, G.A.1    Leonard, E.2
  • 10
    • 0036367321 scopus 로고    scopus 로고
    • The role of protease inhibitor therapy in children with HIV infection
    • Gavin PJ, Yogev R. The role of protease inhibitor therapy in children with HIV infection. Pediatr Drugs. 2002;4:581-607.
    • (2002) Pediatr Drugs , vol.4 , pp. 581-607
    • Gavin, P.J.1    Yogev, R.2
  • 11
    • 0043206923 scopus 로고    scopus 로고
    • Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377
    • Floren LC, Wiznia A, Hayashi S, et al. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics. 2003;112(Suppl):e220-e227.
    • (2003) Pediatrics , vol.112 , Issue.SUPPL.
    • Floren, L.C.1    Wiznia, A.2    Hayashi, S.3
  • 12
    • 0037530630 scopus 로고    scopus 로고
    • The reliability of reports of medical adherence from children with HIV and their adult caregivers
    • Dolezal C, Mellins C, Brackis-Cott E, et al. The reliability of reports of medical adherence from children with HIV and their adult caregivers. J Pediatr Psychol. 2003;28:355-361.
    • (2003) J Pediatr Psychol , vol.28 , pp. 355-361
    • Dolezal, C.1    Mellins, C.2    Brackis-Cott, E.3
  • 13
    • 0037004627 scopus 로고    scopus 로고
    • Supervised interruptions of antiretroviral therapy
    • Deeks S, Hirschel B. Supervised interruptions of antiretroviral therapy. AIDS. 2002;16(Suppl):S157-S169.
    • (2002) AIDS , vol.16 , Issue.SUPPL.
    • Deeks, S.1    Hirschel, B.2
  • 14
    • 0042431969 scopus 로고    scopus 로고
    • Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus
    • Lawrence J, Mayers DL, Hullsiek KH, et al. for the Study Team of the Terry Beirn Community Programs for Clinical Research on AIDS. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med. 2003;349:837-846.
    • (2003) N Engl J Med , vol.349 , pp. 837-846
    • Lawrence, J.1    Mayers, D.L.2    Hullsiek, K.H.3
  • 16
    • 0000771140 scopus 로고
    • 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age
    • Centers for Disease Control and Prevention. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years of age. CDC Morb Mortal Wkly Rep. 1994;44:1-10.
    • (1994) CDC Morb Mortal Wkly Rep , vol.44 , pp. 1-10
  • 17
    • 0036532103 scopus 로고    scopus 로고
    • Nucleoside-analogue(s) reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pre-treated children infected with HIV-1
    • Pediatrics AIDS Clinical Trials Group 377 Study Team
    • Krogstad P, Lee S, Johnson G, et al. Pediatrics AIDS Clinical Trials Group 377 Study Team. Nucleoside-analogue(s) reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pre-treated children infected with HIV-1. Clin Infect Dis. 2002;34:991-1001.
    • (2002) Clin Infect Dis , vol.34 , pp. 991-1001
    • Krogstad, P.1    Lee, S.2    Johnson, G.3
  • 18
    • 0037318501 scopus 로고    scopus 로고
    • Practical applications of viral fitness in clinical practice
    • Bates M, Wrin T, Huang W, et al. Practical applications of viral fitness in clinical practice. Curr Opin Infect Dis. 2003;16:11-18.
    • (2003) Curr Opin Infect Dis , vol.16 , pp. 11-18
    • Bates, M.1    Wrin, T.2    Huang, W.3
  • 19
    • 0042825484 scopus 로고    scopus 로고
    • Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance
    • Campo RE, Rosa I, Lichtenberger PN, et al. Effect of class-specific therapy interruption on persistence of HIV type 1 antiretroviral resistance. AIDS Res Hum Retroviruses. 2003;19:653-656.
    • (2003) AIDS Res Hum Retroviruses , vol.19 , pp. 653-656
    • Campo, R.E.1    Rosa, I.2    Lichtenberger, P.N.3
  • 20
    • 2142713131 scopus 로고    scopus 로고
    • The immune response to AIDS virus infection: Good, bad or both
    • Deeks SG, Walker BD. The immune response to AIDS virus infection: good, bad or both. J Clin Invest. 2004;113:808-810.
    • (2004) J Clin Invest , vol.113 , pp. 808-810
    • Deeks, S.G.1    Walker, B.D.2
  • 21
    • 2342591920 scopus 로고    scopus 로고
    • Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia
    • Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 2004;18:981-989.
    • (2004) AIDS , vol.18 , pp. 981-989
    • Karlsson, A.C.1    Younger, S.R.2    Martin, J.N.3
  • 22
    • 9144231780 scopus 로고    scopus 로고
    • Strong cell-mediated immune responses are associated with the maintenance of low level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1
    • Deeks SG, Martin JN, Sinclair E, et al. Strong cell-mediated immune responses are associated with the maintenance of low level viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J Infect Dis. 2004;189:312-321.
    • (2004) J Infect Dis , vol.189 , pp. 312-321
    • Deeks, S.G.1    Martin, J.N.2    Sinclair, E.3
  • 23
    • 27144433671 scopus 로고    scopus 로고
    • Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients
    • Legrand FA, Abadi J, Jordan KA, et al. Partial treatment interruption of protease inhibitors augments HIV-specific immune responses in vertically infected pediatric patients. AIDS. 2005;19:1575-1585.
    • (2005) AIDS , vol.19 , pp. 1575-1585
    • Legrand, F.A.1    Abadi, J.2    Jordan, K.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.